Atea Pharmaceuticals closed at $4.17 on Nov 3, up 1.71%, 32.2% below its 52-week closing high. Volume of 391.3K shares was 1.29× its 20-day average (above normal).
Split-adjusted performance: -18.7% over one month, -25.5% over six months, +28.3% over one year.
Short interest was 3.1M shares at the Oct 15 settlement, down 61.1% from the prior report (5.0% of float, 10.7 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| AVIRAtea Pharmaceuticals | $4.17 | +1.71% | −25.5% | — | — | — | $334.5M | |
| GALTGalectin Therapeutics | $3.35 | +0.60% | +50.2% | — | — | — | $337.8M | Compare |
| IRDOpus Genetics | $3.93 | +6.22% | −24.4% | −73.8% | −1072.6% | — | $327.0M | Compare |
| EBSEmergent Biosolutions | $6.25 | −2.95% | −30.9% | +66.3% | −76.9% | — | $320.5M | Compare |
| CTNMContineum Therapeutics | $9.69 | +1.36% | −32.7% | — | — | — | $364.5M | Compare |
| VOGXVogenx | $20.53 | −1.01% | — | — | — | — | $305.0M | Compare |
| SPRYARS Pharmaceuticals | $3.05 | 0.00% | −66.2% | +114.2% | −185.2% | — | $303.3M | Compare |
| ENTAEnanta Pharmaceuticals | $10.37 | −0.58% | −28.4% | −21.6% | −135.8% | — | $302.0M | Compare |
| PRLDPrelude Therapeutics Incorporated | $3.78 | −1.56% | −19.1% | — | −244.1% | — | $301.7M | Compare |
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
